Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 5/20 | 0.44 |
| ▸ | CTSK | P43235 | 4/20 | 0.44 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 4/20 | 0.42 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204255 | 1.00 | CYP26A1 (0.44) | CYP26A1CTSKCTSSHRH4CYP19A1 | |
| SCHEMBL7284532 | 0.80 | HRH4 (0.55) | CYP26A1CTSKCTSSHRH4CYP19A1 | |
| SCHEMBL201199 | 0.77 | CYP2B6 (0.36) | CYP26A1 | |
| SCHEMBL201200 | 0.77 | CYP2B6 (0.36) | CYP26A1 | |
| SCHEMBL7298338 | 0.71 | CYP1A2 (0.53) | CTSKCTSSCYP1A2CASP1CTSB | |
| SCHEMBL22236504 | 0.71 | CYP26A1 (0.57) | CYP26A1HRH4CYP1A2PADI4 | |
| SCHEMBL16359763 | 0.70 | CYP1A2 (0.47) | CYP1A2 | |
| SCHEMBL26130427 | 0.70 | CYP1A2 (0.60) | CTSKCTSSCYP1A2CASP1CTSB | |
| SCHEMBL26130430 | 0.70 | CYP1A2 (0.60) | CTSKCTSSCYP1A2CASP1CTSB | |
| SCHEMBL5885746 | 0.69 | CTSK (0.47) | CTSKCTSSCYP1A2CASP1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2338878-A2 | N-hydroxyamide derivatives possessing antibacterial activity | Vicuron Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
| EP-1963262-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007069020-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | NAAA, HDHD5, HACL2 | CYP26A1 1198/4885CTSK 2261/4885CTSS 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.